Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 621 to 630 of 1113 total matches.

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
of miscarriage with exposure during pregnancy or around the time of conception (weak data) Risk of fetal renal ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
were 50-60% lower at day 361 in subjects who developed ADA than in those who did not. Limited data ...
The FDA has approved nirsevimab-alip (Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7   doi:10.58347/tml.2023.1685a |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
in moderate to severe UC. Indirect data suggest that infliximab is more effective than adalimumab ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
pregnancy (when used for weight loss) ■ Thyroid C-cell tumors (animal data) ■ Acute gallbladder disease ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction

Vasodilators For Congestive Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 1988  (Issue 758)
of this subject (Volume 26, page 115, 1984), some additional data have become available. NITRATES — Oral ...
Vasodilators are widely used for treatment of congestive heart failure (CHF) that has not responded adequately to diuretics and digitalis. Vasodilator drugs redistribute blood volume in patients with heart failure, lowering pressure and reducing volume in the failing left ventricle, which leads to increased cardiac output, decreased pulmonary capillary wedge pressure, and improved exercise tolerance. Since the last Medical Letter review of this subject (Volume 26, page 115, 1984), some additional data have become available.
Med Lett Drugs Ther. 1988 Jan 29;30(758):13-4 |  Show IntroductionHide Introduction

Conjugated Haemophilus Influenzae Type b Vaccine

   
The Medical Letter on Drugs and Therapeutics • Apr 22, 1988  (Issue 764)
to the Average Wholesale Price listings in Drug Topics Red Book Data Base Services. The cost to the patient ...
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid (ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older, unconjugated H. influenzae vaccines (b- Capsa I; Hibimune; HibVAX) previously reviewed in The Medical Letter (Volume 27, page 61, 1985).
Med Lett Drugs Ther. 1988 Apr 22;30(764):47-8 |  Show IntroductionHide Introduction

Microx

   
The Medical Letter on Drugs and Therapeutics • Jun 17, 1988  (Issue 768)
appears to be effective in many patients with mild to moderate hypertension. Limited data indicate ...
Microx (Pennwalt), a new low-dosage formulation of the thiazide-type diuretic metolazone (Zaroxolyn; Diulo), was recently marketed in the USA. The manufacturer claims that the low dose of controls hypertension with less potassium loss, making it safer than other diuretics and as effective as combination drugs, such as Dyazide, that include both a thiazide and a potassium-sparing diuretic. Medical Letter consultants generally do not recommend Dyazide or other fixed-dose combinations for treatment of hypertension.
Med Lett Drugs Ther. 1988 Jun 17;30(768):63-4 |  Show IntroductionHide Introduction

Terconazole For Candida Vaginitis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988  (Issue 782)
with metabolism of other drugs is unknown. CONCLUSION — More data are needed to determine whether terconazole ...
Terconazole (Terazol - Ortho), an imidazole derivative, was recently marketed in the USA for treatment of vulvovaginal candidiasis. It is available both as a 0.4% vaginal cream (Terazol 7) and in 80-mg vaginal suppositories (Terazol 3).
Med Lett Drugs Ther. 1988 Dec 30;30(782):118-9 |  Show IntroductionHide Introduction

Adjuvant Chemotherapy of Early Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • May 18, 1990  (Issue 818)
); some substitute doxorubicin (Adriamycin) for methotrexate (CAF). Limited data have not demonstrated ...
The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free of disease; about 30% will have relapsed or died. Patients with positive nodes may have a 30% to 60% relapse rate, depending on the number of positive nodes and other prognostic factors, such as the presence of estrogen receptors (IC Henderson et al, in VT DeVita, Jr et al, eds, Cancer: Principles and Practice of Oncology, 3rd ed, Philadelphia:Lippincott, 1989, p 1197). Which of...
Med Lett Drugs Ther. 1990 May 18;32(818):49-50 |  Show IntroductionHide Introduction

Ophthalmic Ciprofloxacin

   
The Medical Letter on Drugs and Therapeutics • May 31, 1991  (Issue 845)
studies are available on its use for treatment of conjunctivitis. RESISTANCE — Few data are available ...
An ophthalmic formulation of ciprofloxacin hydrochloride (Ciloxan - Alcon), a fluoroquinolone antibiotic, was recently marketed in the USA for treatment of bacterial keratitis and conjunctivitis. Ciprofloxacin has been used orally (Cipro) to treat a variety of serious infections (Medical Letter, 30:11, 1988) and recently was approved for intravenous administration.
Med Lett Drugs Ther. 1991 May 31;33(845):52-3 |  Show IntroductionHide Introduction